Literature DB >> 17205458

Drug resistance after failure of initial antiretroviral therapy in resource-limited countries.

Joel E Gallant.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 17205458     DOI： 10.1086/510752

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  14 in total

1.  Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings.

Authors:  Holly E Rawizza; Beth Chaplin; Seema T Meloni; Geoffrey Eisen; Tara Rao; Jean-Louis Sankalé; Abdoulaye Dieng-Sarr; Oche Agbaji; Daniel I Onwujekwe; Wadzani Gashau; Reuben Nkado; Ernest Ekong; Prosper Okonkwo; Robert L Murphy; Phyllis J Kanki
Journal:  Clin Infect Dis       Date:  2011-12       Impact factor: 9.079

2.  Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region.

Authors:  Sanjay Pujari; Preeyaporn Srasuebkul; Somnuek Sungkanuparph; Poh Lian Lim; Nagalingeswaran Kumarasamy; John Chuah; Ritesh N Kumar; Yi-Ming A Chen; Shinichi Oka; Jun Yong Choi; Man-Po Lee; Praphan Phanuphak; Adeeba Kamarulzaman; Christopher Lee; Zhang Fujie; Rosanna Ditangco; Vonthanak Saphonn; Thira Sirisanthana; Tuti Parwati Merati; Jeff Smith; Matthew G Law
Journal:  J Antivir Antiretrovir       Date:  2009-11-01

3.  Antiretroviral therapy as HIV prevention: status and prospects.

Authors:  Kenneth H Mayer; Kartik K Venkatesh
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

4.  HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naïve to HAART in Cameroon.

Authors:  Sherri T Burda; Ragupathy Viswanath; Jiangqin Zhao; Thompson Kinge; Christopher Anyangwe; Erick T Tinyami; Bijayesh Haldar; Rebecca L R Powell; Veronica Jarido; Indira K Hewlett; Phillipe N Nyambi
Journal:  J Med Virol       Date:  2010-02       Impact factor: 2.327

5.  Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients.

Authors:  N Kumarasamy; Kartik K Venkatesh; Bella Devaleenal; S Poongulali; Tokugha Yepthomi; Suniti Solomon; Timothy P Flanigan; Kenneth H Mayer
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2011-01-24

6.  Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa.

Authors:  Julie H Levison; Catherine Orrell; Elena Losina; Zhigang Lu; Kenneth A Freedberg; Robin Wood
Journal:  Antivir Ther       Date:  2011

7.  Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.

Authors:  Sanjay Pujari; Ameet Dravid; Nikhil Gupte; Kedar Joshi; Vivek Bele
Journal:  Medscape J Med       Date:  2008-08-20

8.  Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings.

Authors:  Adedotun A Adetunji; Chad Achenbach; Joseph Feinglass; Kristin M Darin; Kimberly K Scarsi; Ernest Ekong; Babafemi O Taiwo; Isaac F Adewole; Robert Murphy
Journal:  J Int Assoc Provid AIDS Care       Date:  2012-11-05

9.  Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India.

Authors:  Sanjay Pujari; Ameet Dravid; Nikhil Gupte; Kedar Joshix; Vivek Bele
Journal:  J Int AIDS Soc       Date:  2008-08-20       Impact factor: 5.396

10.  Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.

Authors:  Alexander O Pasternak; Suzanne Jurriaans; Margreet Bakker; Jan M Prins; Ben Berkhout; Vladimir V Lukashov
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.